Date: 2015-07-22
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: Pfizer (USA - NY)
Product: PF-06751979
Action mechanism:
Disease: Alzheimer\'s disease
Therapeutic area: Neurodegenerative diseases
Country: USA
Trial
details: This phase 1, randomized, double-blind, sponsor-open, placebo controlled first-in-human trial will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of Pf-06751979 following oral doses in healthy adult and healthy elderly subjects. (NCT02509117)
Latest news:
